ABSTRACT
Gene discoveries in obesity have largely relied on homogeneous populations, limiting their generalizability across ancestries. We performed a gene-based rare variant association study of BMI on 839,110 individuals from six ancestries across two population-scale biobanks. A cross-ancestry meta-analysis identified 13 genes, including five novel ones: YLPM1, RIF1, GIGYF1, SLC5A3, and GRM7, that conferred about three-fold risk for severe obesity, were expressed in the brain and adipose tissue, and were linked to obesity traits such as body-fat percentage. While YLPM1, MC4R, and SLTM showed consistent effects, GRM7 and APBA1 showed significant ancestral heterogeneity. Polygenic risk additively increased obesity penetrance, and phenome-wide studies identified additional associations, including YLPM1 with altered mental status. These genes also influenced cardiometabolic comorbidities, including GIGYF1 and SLTM towards type 2 diabetes with or without BMI as a mediator, and altered levels of plasma proteins, such as LECT2 and NCAN, which in turn affected BMI. Our findings provide insights into the genetic basis of obesity and its related comorbidities across ancestries and ascertainments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the NIH GM121907 grant
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study were obtained after permissions from the UKB and All of Us portals. The Penn State IRB did not consider them as human subjects research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In this version, we have made the following changes: (1) Expanded our analysis by incorporating 150,000 additional Whole Genome Sequencing (WGS) samples from the latest All of Us release, increasing our total sample size to 839,110. (2) Implemented an ancestry-wise inverse variance-weighted fixed-effect meta-analysis for rare variant gene burden associations. This approach replaces the previously used population-based random-effects meta-analysis, which is more susceptible to population stratification bias and potential false-positive associations. (3) The larger sample size and improved meta-analysis strategy resulted in a substantially smaller number of identified obesity-associated genes compared to our previous findings, suggesting a more refined and robust discovery framework.
Data Availability
All data produced in the present work are contained in the manuscript
